Search / Trial NCT00001121

A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of December 26, 2024

Completed

Keywords

Placebos Aids Vaccines Follow Up Studies Hiv Therapeutic Vaccine

ClinConnect Summary

There are many possible outcomes of HIV-1 infection among persons who receive experimental HIV-1 vaccines. In the best-case scenario, these vaccines may prevent infection (sterilizing immunity). However, current viral vaccines are thought to limit, but not prevent, virus replication after infection. In the latter case, it is important to document the effect of the immune response on the disease course as reflected by viral load, the evolution of the viral quasi species, and clinical symptoms over time. Understanding the evolution of the immune response in vaccinees after subsequent exposure...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Patients may be eligible for this study if they:
  • Become infected with HIV while participating in HIVNET 014, or if they are an HIV-positive partner (sexual or needle-sharing) of a HIVNET 014A participant.
  • Are able and willing to provide written informed consent.
  • Exclusion Criteria
  • Patients will not be eligible for this study if they:
  • Have a serious psychiatric or psychological disorder that would prevent them from completing the study.

Trial Officials

Connie Celum

Study Chair

Susan Buchbinder

Study Chair

Haynes Sheppard

Study Chair

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Seattle, Washington, United States

Bronx, New York, United States

New York, New York, United States

Philadelphia, Pennsylvania, United States

Providence, Rhode Island, United States

Pawtucket, Rhode Island, United States

San Francisco, California, United States

Denver, Colorado, United States

Chicago, Illinois, United States

Boston, Massachusetts, United States

Chicago, Illinois, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials